期刊文献+

牛津病理分类方法在IgA肾病中的临床应用研究 被引量:3

Study of the clinical applicability of the Oxford pathological classification for IgA nephropathy
下载PDF
导出
摘要 目的探讨牛津病理分类方法对IgA肾病患者的临床适用性。方法收集120例IgA肾病患者的临床及病理资料,根据牛津病理分类方法中的系膜细胞增生(M)、节段性肾小球硬化(S)、毛细血管内细胞增生(E)、肾小管萎缩及间质纤维化(T)等4项病理指标分组,比较不同病理指标者的临床资料差异,分析牛津病理分类方法及Haas分型方法的相关性及其分别与尿蛋白定量及肾小球滤过率(GFR)的相关性。结果 M0组与M1组间IgA肾病患者平均动脉压、尿蛋白定量及血尿酸水平比较差异有统计学意义(P<0.05)。E0组与E1组间IgA肾病患者尿蛋白定量比较差异有统计学意义(P<0.05)。S0组与S1组间IgA肾病患者平均动脉压、尿蛋白定量、血尿酸、GFR及血脂水平比较差异有统计学意义(P<0.05)。T0组与T1/T2组间IgA肾病患者平均动脉压、尿蛋白定量、血尿酸、GFR及血甘油三酯比较差异有统计学意义(P<0.05)。牛津病理分类方法与Haas分型法呈正相关(r=0.747,P<0.05),并且均与IgA肾病患者的GFR、尿蛋白定量有关(P均<0.05)。结论牛津病理分类方法各个病理指标与IgA肾病临床指标相关。牛津病理分类方法与Haas分型方法具有良好的相关性,对IgA肾病具有临床适用性。 Objective To study the eorrelation between the Oxford classification and the Haas's clas- sification, and to analysis the relationship between pathological variables of the Oxford classification and clinical indicators. Methods Clinic and pathological datas of 120 patients diagnosed as primary IgA nephropathy were collected. The Oxford classification score ( mesangial hypercellularity score M0/M1, endocapillary hypercellu- larity score E0/E1, segmental glomerular sclerosis score SO/S1 and tubular atrophy and interstitial fibrosis score T0/T1/T2) and the Haas's classification ( I ~ V grade) were performed, . Correlation between Oxford classification and Haas's classification, their correlation with 24 hour urinary protein and glomerular filtration rate were estimated. , Samples were divide into: the M0 and M1 group, E0 and E1 group, SO and S1 group, TO and T1/T2 groups, according to the pathological various score of the Oxford classification, and were eom- pared with different clinical data. Results The Oxford classification was significantly correlated with the Haas's classification, ( r = 0. 747, P 〈 0. 05 ). Both pathology classifications were negatively correlated with esti- mated glomerular filtration rate, and positively correlated with 24-hour urine protein with significant difference. 24 hours urinary protein, MAP and serum uric acid between M0 and M1 group were significantly different (P 〈 0. 05 ) ; 24 hours urinary protein between E0 and E1 group was significantly different ( P 〈 0. 05 ) ; 24 hours u- rinary protein, MAP, uric acid, estimated glomerular filtration rate and lipids were significantly different ( P 〈 0. 05 ) between SO and S1 group ; 24-hour urine protein, MAP, serum uric acid, glomerular filtration rate and blood triglyeeride are significantly different ( P 〈 0. 05 ) between the TO and T1/T2 group. Conclusion The Oxford classification has a positive correlation with the Haas's classification. It was applicable for clinical assess- ment. The pathological various of the Oxford classification were associated with clinical various.
出处 《新医学》 2013年第10期689-693,共5页 Journal of New Medicine
关键词 IGA肾病 牛津病理分类方法 Haas分型法 IgA nephropathy Oxford classification Haas's classification
  • 相关文献

参考文献11

  • 1陈蓉,程骏章.IgA肾病发病机制的研究进展[J].新医学,2012,43(11):816-819. 被引量:4
  • 2Zhou FD, Zhao MH, Zou WZ, el al. The changing spectrum of primary glomerular diseases within 15 years: a survery of 3331 patients in a single Chinese centre, Nephrol Dial Transplant, 2009, 24: 870-876.
  • 3Haas M. Histology and immunohistology of IgA nephrop?athy.J Nephrol, 2005, 18: 676-680.
  • 4Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, et al . The Oxford classification of IgA ne?phropathy: pathology definitions, correlations, and re?producibility. Kidney Int, 2009, 76: 546-556.
  • 5Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, et ai, The Oxford Classification of IgA ne?phropathy: rationale, clinicopathological correlations and classification. Kidney Int, 2009, 76: 534-545.
  • 6Xie Y, Chen X. Epidemiology, major outcomes, risk factors, prevention and management of chronic kidney disease in China. AmJ N ephrol, 2008, 28: 1-7.
  • 7Shen P, He L, Huang D. Clincial course and prognostic factors of clinically early IgA nephropathy. NethJ Med, 2008, 66: 242-247.
  • 8Jiang L, Liu G, LvJ, et al. Concise semiquantitative histological scoring system for immunoglobulin A ne?phropathy. Nephrology (Carlton), 2009, 14: 597- 605.
  • 9Komatsu H, Fujimoto S, Sato Y, et al. "Point of no re?turn (PNR)" progressive IgA in nephropathy: signifi- cance of blood pressure and proteinuriamanagement up to PNR.J Nephrol, 2005, 18: 690-695.
  • 10RichardJ, Glassock MD, IgA nephropathy: challenges and opportunities. Cleve ClinJ Med, 2008, 75: 569- 576.

二级参考文献20

  • 1李卫鹏,王福庆.CD4^+CD25^+ Treg的免疫调节作用机制以及临床研究进展[J].现代免疫学,2006,26(2):164-167. 被引量:18
  • 2YUSUKE S, HISTOSHI S, JUNICHIRO N, et al. Pa- thylogical role of tonsillar B cells in IgA nephropathy di- vision of nephropathy [ J ] . Clin Dev Immunol, 2011, Epub 2011 Jul 18.
  • 3TANAKA M, SEKI G, SOMEYA T, et al. Aberrantly glycosylated lgA1 as a factor in the pathogenesis of IgA nephropathy [ J] . Clin Dev Immunol, 2011 : 470803.
  • 4HASTINGS M C, MOLDOVEANU Z, JULIAN B A, et al. Galactose-deficiencient IgA 1 in African Americans with IgA nephropathy: serum levels and heritability [J]. ClinJ Am Soe Nephrol, 2011, 5 (11): 2069- 2074.
  • 5GAHAVI A G, MOLDOVVEAN Z, WYATT R J, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy [ J ]. Am Soc Nephrol, 2008, 19 (5): 1008-1014.
  • 6MALYCHA F, EGGERMANN T, HRISTOV M, et al. No evidence for a role of cosmc-charperone mutations in European IgA nephropathy patients[J]. Nephrol Dial Trar]splant, 2009, 24 ( 1 ) : 321-324.
  • 7YAMADA K, KOBAYASHI N, IKEDA T, et al. Down- regulation of core 1 beta 1 , 3 -galactosyhransferase and cosmc by Th2 cytokine aherso-glycosylation of IgA1 [J] . Nephrol Dial Transplant , 2010 , 25 (12) : 3890-3897.
  • 8SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al. Pillars article: immunologic self-tolerance main- tained by activated T cells expressing IL-2 receptor al- pha-chain (CD25) . Breakdown of single mechanism of self-tolerance causes various autoirnmune disease. J. Immunol. 1995. [J]. J Immunol, 2011, 186 (7) ; 3808-3821.
  • 9FONTENOTET J D, GAVIN M A, RUDENSKY A Y, et al. Foxp3 programs the development and function of CD4^+ CD25^+ regulatory T cells [ J ] . Nat Immuol, 2003.4 (4): 330-336.
  • 10HUANG H, PENG Y, LIU F, et al. Is IgA nephropa- thy induced by abnormalities of CD4^+ CD25^+ cells in the tonsils? [ J ]. Med Hypotheses, 2007, 69 ( 2 ) : 410-413.

共引文献3

同被引文献31

  • 1郑春燕,琚玮,黄生生.郑建民教授治疗IgA肾病经验[J].中医研究,2006,19(2):44-45. 被引量:11
  • 2陈香美,陈以平,周柱亮,陈建,魏日胞,邓跃毅,何亚妮,李平,李建军,罗健华.肾乐胶囊治疗IgA肾病肺脾气虚证患者的前瞻性多中心随机对照临床研究[J].中国中西医结合杂志,2006,26(12):1061-1065. 被引量:37
  • 3Coppo R,D'Amico G.Factors predicting progression of Ig A nephropathies[J].J Nephrol,2005,18(5):503-512.
  • 4Schena FP.A retrospective analysis of the natural history of primary Ig A nephropathy worldwide[J].Am J Med,1990,89(2):209-215.
  • 5Coppo R.Pediatric Ig A nephropathy:clinical and therapeutic perspectives[J].Semin Nephrol,2008,28(1):18-26.
  • 6Yoshikawa N,Tanaka R,Iijima K.Pathophysiology and treatment of Ig A nephropathy in children[J].Pediatr Nephrol,2001,16(5):446-457.
  • 7van der Boog PJ,van Kooten C,de Fijter JW,et al.Role of macromolecular Ig A in Ig A nephropathy[J].Kidney Int,2005,67(3):813-821.
  • 8Hwang VJ,Ulu A,van Hoorebeke J,et al.Biomarkers in Ig A nephropathy[J].Biomark Med,2014,8(10):1263-1277.
  • 9Ishiguro C,Yaguchi Y,Funabiki K,et al.Serum IgA/C3 ratio may predict diagnosis and prognostic grading in patients with IgA nephropathy[J].Nephron,2002,91(4):755-758.
  • 10Maeda A,Gohda T,Funabiki K,et al.Significance of serum IgA levels and serum IgA/C3ratio in diagnotic analysis of patients with IgA nephropathy[J].J Clin Lab Anal,2003,17(3):73-76.

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部